Black Hawk Acquisition Corp (BKHA): Cash & Equivalents
$0
As of 2025-11-30
$0
As of 2026-08-31
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-11-30 | $0 | n/a | 2026-03-06, Balance as of period end |
| 2024-11-30 | $0 | n/a | 2026-03-06, Balance as of period end |
| 2023-11-30 | $0 | n/a | 2025-02-07, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Black Hawk Acquisition Corp (BKHA) | 2025-11-30 | $0 | n/a |
| Pluri Inc. (PLUR) | 2026-06-30 | $3.53M | -40.1% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $8.48M | -66.1% |
| Curis Inc (CRIS) | 2025-12-31 | $5.06M | -74.7% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $8.08M | -45.9% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $24.75M | +18.3% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $7.11M | -17.9% |
| Jasper Therapeutics, Inc. (JSPR) | 2025-12-31 | $28.69M | -59.9% |
| MiNK Therapeutics, Inc. (INKT) | 2025-12-31 | $13.36M | +191.9% |
Compare BKHA, PLUR, ATRA, CRIS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗